ZFIN ChEBI: N-acylpyrrolidine

Relationships

is a type of: amide pyrrolidines

amide pyrrolidines Show first 5 Terms
has subtype: (1S)-2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine (1S)-2-[(2S,5R)-2-(aminomethyl)-5-prop-1-yn-1-ylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine (2S)-2-cyano-1-(4-phenyl-L-phenylalanyl)pyrrolidine (2S)-3-(3-pyridyl)propyl 1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine-2-carboxylate (2S)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-({(3R)-1-[(1Z)-ethanimidoyl]pyrrolidin-3-yl}oxy)phenyl]propanoic acid ... Show All 73 Terms

(1S)-2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine (1S)-2-[(2S,5R)-2-(aminomethyl)-5-prop-1-yn-1-ylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine (2S)-2-cyano-1-(4-phenyl-L-phenylalanyl)pyrrolidine (2S)-3-(3-pyridyl)propyl 1-(3,3-dimethyl-1,2-dioxopentyl)pyrrolidine-2-carboxylate (2S)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-({(3R)-1-[(1Z)-ethanimidoyl]pyrrolidin-3-yl}oxy)phenyl]propanoic acid (2S)-3-methyl-2-((2R,3S)-3-[(methylsulfonyl)amino]-1-{[2-(pyrrolidin-1-ylmethyl)-1,3-oxazol-4-yl]carbonyl}pyrrolidin-2-yl)butanoic acid (2S,3S)-3-{3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-oxo-1-pyrrolidin-1-ylbutan-2-amine (2S,4R)-1-acetyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-(benzothiazol-2-ylcarbonyl)butyl]-4-hydroxypyrrolidine-2-carboxamide (2S,4S,5R)-1-(4-tert-butylbenzoyl)-2-isobutyl-5-(1,3-thiazol-2-yl)pyrrolidine-2,4-dicarboxylic acid (2S,4S,5R)-2-isobutyl-5-(2-thienyl)-1-[4-(trifluoromethyl)benzoyl]pyrrolidine-2,4-dicarboxylic acid (3S)-1-[(E)-amino(imino)methyl]-N-({(2S)-1-[N-(2-naphthylsulfonyl)-L-seryl]pyrrolidin-2-yl}methyl)piperidine-3-carboxamide (3S)-1-{[(3,5-dimethylisoxazol-4-yl)amino]carbonyl}-4,4-dimethylpyrrolidin-3-yl {(1S)-1-[1-hydroxy-2-oxo-2-{[(1R)-1-phenylethyl]amino}ethyl]pentyl}carbamate (4S)-1-[(4-butoxyphenyl)sulfonyl]-N-hydroxy-4-[(methylsulfonyl)amino]-D-prolinamide (4S)-N-hydroxy-4-(methoxyamino)-1-[(4-methoxyphenyl)sulfonyl]-D-prolinamide (E)-1-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-methyldec-8-ene-1,3-dione 1-(3-mercapto-2-methylpropionyl)pyrrolidine-2-carboxylic acid 1-[(2E,4E)-2,4-decadienoyl]pyrrolidine 1-[(2E,4E)-2,4-dodecadienoyl]pyrrolidine 1-[(2E,4E,6E)-2,4,6-dodecatrienoyl]pyrrolidine 1-[(3aR)-5-{[3-(2,4-difluorophenyl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl]carbonyl}-6-methoxy-3aH-pyrrolo[2,3-b]pyridin-3-yl]-2-[(3R)-3-hydroxypyrrolidin-1-yl]-2-oxoethanone 1-[2-[3-(1-propan-2-ylsulfonylazetidin-3-yl)-1,2,4-oxadiazol-5-yl]pyrrolidin-1-yl]ethanone 1-[3,3-dimethyl-2-(2-2-methylaminopropionylamino)butyryl]-4-phenoxypyrrolidine-2-[N-(1,2,3,4-tetrahydronaphthalen-1-yl)]carboxamide 1-propanoylproline 1-{[1-(2-amino-3-phenylpropionyl)pyrrolidine-2-carbonyl]amino}-2-(3-cyanophenyl)ethaneboronic acid 2-[4-({(S)-1-[((S)-2-{[(RS)-3,3,3-trifluoro-1-isopropyl-2-oxopropyl]aminocarbonyl}pyrrolidin-1-yl)carbonyl]-2-methylpropyl}aminocarbonyl)benzoylamino]acetic acid 2-[4-({2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-2-oxoethyl}amino)-4-methylpiperidin-1-yl]isonicotinic acid 2-amino-3-methyl-1-pyrrolidin-1-ylbutan-1-one 4-{[(2R,5S)-5-{[(2S)-2-(aminomethyl)pyrrolidin-1-yl]carbonyl}pyrrolidin-2-yl]methoxy}-3-tert-butylbenzoic acid 4-{[(E)-amino(imino)methyl]amino}-N-({(2S)-1-[N-(2-naphthylsulfonyl)-L-seryl]pyrrolidin-2-yl}methyl)butanamide 6-(4-{(1S,2S)-2-amino-1-[(dimethylamino)carbonyl]-3-[(3S)-3-fluoropyrrolidin-1-yl]-3-oxopropyl}phenyl)-1H-[1,2,4]triazolo[1,5-a]pyridin-4-ium 13-O-methylviriditin [(R)-1-L-prolylpyrrolidin-2-yl]boronic acid aniracetam captopril dextromoramide elbasvir Formosusin A Formosusin B Formosusin C Isomalyngamide B LCL161 ledipasvir LSM-1512 malyngamide B methyl 4-{[({[(2R,5S)-5-{[(2S)-2-(aminomethyl)pyrrolidin-1-yl]carbonyl}pyrrolidin-2-yl]methyl}amino)carbonyl]amino}benzoate N(2)-[(benzyloxy)carbonyl]-N(1)-((3R)-1-{N-[(benzyloxy)carbonyl]-L-leucyl}-4-oxopyrrolidin-3-yl)-L-leucinamide N-(2-methyl-3-oxodecanoyl)pyrrolidine N-(14-Methylhexadecanoyl)pyrrolidine N-(trans-4-{(1S,2S)-2-amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl}cyclohexyl)-N-methylacetamide N-({(2S)-1-[(3R)-3-amino-4-(2-fluorophenyl)butanoyl]pyrrolidin-2-yl}methyl)benzamide N-[(2R,3S)-1-((2S)-2-{[(cyclopentylamino)carbonyl]amino}-3-methylbutanoyl)-2-(1-formylcyclobutan-1-yl)pyrrolidin-3-yl]cyclopropanecarboxamide N-[4-(D-prolinosulfonyl)benzoyl]-L-glutamic acid N-[4-(morpholin-4-ylcarbonyl)benzoyl]-L-valyl-N-[(3S)-5,5,6,6,6-pentafluoro-2-methyl-4-oxohexan-3-yl]-L-prolinamide N-acetyl-D-proline N-acetyl-L-proline N-Acetylhomoproline N-acetylpyrrolidine N-acetyltryptophyl-N(1)-{3-[1-(N-acetyltryptophylvalyl)pyrrolidin-2-yl]-1-benzyl-2,3-dihydroxypropyl}valinamide N-benzyloxycarbonyl-L-prolyl-L-prolinal N-Hexadecanoylpyrrolidine N-{(2S,3R)-2-[(1S)-1-formyl-2-methylpropyl]-1-[(2E)-4-piperidin-1-ylbut-2-enoyl]pyrrolidin-3-yl}methanesulfonamide Nosperin numidargistat PF-956980 PHA-665752 piperyline Scalusamide B Scalusamide C Talarotoxin tert-butyl {1-[2-(1-formylpropyl)-3-methanesulfonylaminopyrrolidine-1-carbonyl]-2-methylpropyl}carbamate Variotin velpatasvir Viriditin Show first 5 Terms

Phenotype

Phenotype resulting from N-acylpyrrolidine

Phenotype where environments contain N-acylpyrrolidine

Phenotype modified by environments containing N-acylpyrrolidine

Human Disease Model